Mavyret, an antiviral medication, has a complex patent landscape, with various patents contributing to its market exclusivity. The primary patent for Mavyret (also known by its generic name, glecaprevir/pibrentasvir) is U.S. Patent No. 9,750,777, which covers the combination of glecaprevir and pibrentasvir [1].
When does Mavyret's main patent expire?
U.S. Patent No. 9,750,777 is set to expire on November 10, 2030 [1]. However, patent expiration dates can be extended due to factors such as patent term adjustments or regulatory delays.
Are there other patents protecting Mavyret?
Beyond the primary patent, Mavyret is protected by numerous other patents. These patents may cover different aspects of the drug, including its composition, methods of use, manufacturing processes, and specific formulations [1]. DrugPatentWatch.com tracks these patents, which can influence the overall period of market exclusivity [2].
How might Mavyret's patent expiration affect drug availability and cost?
Upon the expiration of key patents, generic versions of Mavyret could become available. This typically leads to increased competition, which can result in lower prices for the medication and a broader range of access for patients [3].
What is Mavyret used to treat?
Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection in adults. It is approved for all genotypes (1 through 6) of HCV [4].
How does Mavyret work?
Mavyret is a combination treatment that includes two active ingredients: glecaprevir and pibrentasvir. Glecaprevir is an NS3/4A protease inhibitor, and pibrentasvir is an NS5A inhibitor. These components work together to block the virus's ability to replicate and spread [4].
What are the potential risks or side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue. In rare cases, Mavyret can cause liver problems, particularly in patients with advanced liver disease who are also taking certain other medications. It is important for patients to discuss their complete medical history and any other medications they are taking with their healthcare provider before starting Mavyret [4].
Who is the manufacturer of Mavyret?
Mavyret was developed by AbbVie [4].
How does Mavyret compare to other hepatitis C treatments?
Mavyret is known for its high cure rates and relatively short treatment duration for most patients. It is often prescribed as a pan-genotypic option, meaning it can treat multiple genotypes of HCV without the need for prior genotype testing in many cases [4]. Other direct-acting antiviral (DAA) regimens exist, and the choice of treatment can depend on factors such as the specific HCV genotype, prior treatment history, and the presence of liver disease [5].
What is the general patent situation for hepatitis C drugs?
The hepatitis C drug market has seen extensive patent activity, with many direct-acting antivirals protected by multiple patents. This has led to significant litigation and challenges to patents by generic manufacturers aiming to enter the market [1][2].
Sources:
[1] DrugPatentWatch.com
[2] https://drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999956/
[4] https://www.mavyret.com/
[5] https://www.hcvguidelines.org/full-report/treatment-naive-patients